中国老年人群四价与三价流感疫苗的成本效果比较
研究采用决策分析模型,比较未接种、三价流感疫苗(TIV)和四价流感疫苗(QIV)在中国69岁老年 hypothetical 队列中的1年临床与经济结局。基础分析显示QIV较TIV成本更高(56.29 vs 54.28美元)但感染率、死亡率和QALY损失更低,ICER为6,700美元/QALY,低于支付意愿阈值(29,580美元/QALY),QIV具有成本效果。
要点
- QIV对比TIV的ICER为6,700美元/QALY,低于支付意愿阈值29,580美元/QALY。
- 蒙特卡洛模拟中QIV、TIV和未接种具有成本效果的概率分别为86.3%、13.7%和0%。
核心结论
- 对于中国老年人群,QIV相比TIV和未接种流感疫苗似乎是一种具有成本效果的选择。
研究设计与样本
- 采用决策分析模型,在假设的中国69岁老年队列中比较未接种、TIV和QIV三种流感疫苗接种方案1年的临床与经济结局。
- 结局指标包括成本、流感感染率、流感相关死亡率、质量调整生命年(QALY)损失和增量成本效果比(ICER),采用社会视角。
- 进行敏感性分析以检验模型输入的不确定性。
主要发现
- 基础分析显示,未接种被TIV和QIV主导(成本更高且QALY损失更高)。
- QIV较TIV成本更高(56.29 vs 54.28美元),但流感感染率更低(0.608 vs 0.623)、死亡率更低(0.00199 vs 0.00204)、QALY损失更低(0.01213 vs 0.01243)。
- QIV对比TIV的ICER为6,700美元/QALY,低于支付意愿阈值29,580美元/QALY。
- 单因素敏感性分析发现QIV的成本效果受QIV相对于TIV疫苗有效性的相对风险影响,若该相对风险低于1.05则TIV具有成本效果。
- 在10,000次蒙特卡洛模拟中,QIV、TIV和未接种具有成本效果的概率分别为86.3%、13.7%和0%。
关键数值与推荐
- QIV对比TIV的ICER为6,700美元/QALY,支付意愿阈值为29,580美元/QALY。
- QIV相对于TIV疫苗有效性的相对风险低于1.05时,TIV具有成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza-associated excess death occurred most in the elderly. We aimed to assess the cost-effectiveness of quadrivalent influenza vaccine (QIV) versus trivalent influenza vaccine (TIV) for prevention of influenza infection among elderly population in China. METHODS: A decision-analytic model was developed to compare 1-year clinical and economic outcomes of three influenza vaccination options (no vaccination, TIV, and QIV) in a hypothetical cohort of Chinese elderly aged 69 years. Outcome measures included cost, influenza infection rate, influenza-related mortality rate, quality-adjusted life-years (QALY) loss, and incremental cost-effectiveness ratio (ICER) from societal perspective. Sensitivity analyses were performed to examine the uncertainty of model inputs. RESULTS: Base-case results showed no vaccination was dominated (more costly at higher QALY loss) by TIV and QIV. QIV was more costly (USD56.29 versus USD54.28) with lower influenza infection rate (0.608 versus 0.623), mortality rate (0.00199 versus 0.00204), and QALY loss (0.01213 versus 0.01243) than TIV. QIV was cost-effective compared to TIV with ICER of 6,700 USD/QALY below the willingness-to-pay threshold (29,580 USD/QALY). One-way sensitivity analysis found the cost-effectiveness of QIV was subject to the relative risk of vaccine effectiveness of QIV versus TIV, and TIV would be cost-effective if the relative risk was below 1.05. In 10,000 Monte Carlo simulations, the probabilities of QIV, TIV, and no vaccination to be cost-effective were 86.3%, 13.7%, and 0%, respectively. CONCLUSION: QIV appears to be a cost-effective option compared to TIV and no influenza vaccination for elderly population in China.
引用
- Jiang M, Li P, Wang W, et al. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. Vaccine. 2019. PMID: 31787414. doi:10.1016/j.vaccine.2019.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。